Trial Profile
Safety and efficacy of avelumab plus carboplatin patients with metastatic castration resistant prostate cancer progressing after one line of chemotherapy and one novel androgen receptor axis inhibitor: A phase Ib study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Carboplatin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 26 Oct 2022 Results assessing Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer published in the British Journal of Cancer
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 02 Jul 2018 New trial record